

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM**

July 13, 2022

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2020/1_DrSwees_premeeting_announcement.pdf
- II. Roll Call
- III. Review of meeting transcript for April 20, 2022, meeting
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2022/04-20-22_DURB_transcript_updated.pdf
- IV. Review of draft meeting summary for April 20, 2022, meeting
- V. Secretary's report
- VI. Old Business
 - A. Hetlioz® liquid formulation use in 16 years old (clarification)
 - B. Denials details from MCO partners
 - C. Ivermectin utilization in drugs category report (April 2022)
 - D. Educational newsletter on oral COVID-19 medications
- VII. New Business
 - A. Addendum to calcitonin gene-related peptide (CGRP) receptor antagonists protocol
 - B. Proposed protocol for Vuity® (pilocarpine ophthalmic)
 - C. Proposed protocol for Paroxysmal Nocturnal Hemoglobinuria (PNH) products
 - D. Proposed protocol for Bylvay® (odevixibat)
- VIII. A. Informational Highlights/Reports
 - 1. Gainwell Technologies/NJ HMO 1st Quarter 2022 Prior Authorization Report
 - 2. Summary of DURB Action Items
 - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report/Physicians Administered Drugs (by amount paid and by category)
 - FFS Top Drugs
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2022/FFS_Top_Drugs_Report_April-2022.pdf
 - MCO Top Drugs
https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2022/MCO_Top_Drugs_Report_March-2022.pdf

FFS Top Drugs by Category

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2022/FFS_Top_Drugs_by_Category_April-2022.pdf

MCO Top Drugs by Category

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2022/MCO_Top_Drugs_by_Category_March-2022.pdf

(b) Antiviral drugs by amount paid

https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/7-2022/FFS_Antiviral_Drugs_April-2022.pdf

B. Medication information:

1. COVID-19 Vaccines information

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>

2. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html> Continuously updated.

3. New Jersey COVID-19 Information Hub (continuously updated)

<https://covid19.nj.gov/>

4. New Jersey COVID-19 Dashboard

https://www.nj.gov/health/cd/topics/covid2019_dashboard.shtml (new) continuously updated

5. Know Your Treatment Options for COVID-19 – FDA

<https://www.fda.gov/consumers/consumer-updates/know-your-treatment-options-covid-19>